Cytek Biosciences, Inc. CTKB NASDAQ

Cytek Biosciences, Inc. (CTKB) reported total assets of $461.54M and total liabilities of $119.8M for fiscal year 2025, resulting in total equity of $341.74M.

The company held $261.53M in cash and short-term investments. Total debt stood at $33.02M, with net debt of $-57.83M. The Debt-to-Equity (D/E) ratio was 0.1 (conservative).

Current ratio is 5.04, indicating strong short-term liquidity. Interest coverage is -85.2x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (49/100) — Total assets $461.54M and equity $341.74M support the company's competitive scale
• VALUE (92/100) — Debt-to-Equity 0.1 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 50/100 with 2/7 criteria passed.

LIVN

LivaNova PLC

$65.14

+0.23%

AXGN

AxoGen, Inc.

$34.76

+0.87%

HSKA

Heska Corporation

$119.99

+0.00%

SRDX

Surmodics, Inc.

$42.98

+0.35%

NPCE

NeuroPace, Inc.

$15.61

+1.69%

OFIX

Orthofix Medical Inc.

$12.87

+1.18%

KIDS

OrthoPediatrics Corp.

$17.85

-0.06%

RXST

RxSight, Inc.

$7.22

-0.69%